Your browser is no longer supported. Please, upgrade your browser.
Settings
ZYME Zymeworks Inc. daily Stock Chart
ZYME [NYSE]
Zymeworks Inc.
Index- P/E- EPS (ttm)-0.35 Insider Own22.10% Shs Outstand31.94M Perf Week12.79%
Market Cap461.85M Forward P/E- EPS next Y-2.63 Insider Trans- Shs Float23.01M Perf Month2.05%
Income-13.10M PEG- EPS next Q-0.27 Inst Own37.70% Short Float2.77% Perf Quarter-5.12%
Sales74.20M P/S6.22 EPS this Y81.60% Inst Trans1.91% Short Ratio5.49 Perf Half Y-15.93%
Book/sh5.31 P/B2.72 EPS next Y-9.10% ROA-8.00% Target Price24.88 Perf Year65.64%
Cash/sh4.70 P/C3.08 EPS next 5Y- ROE-9.20% 52W Range7.26 - 29.00 Perf YTD90.44%
Dividend- P/FCF36.95 EPS past 5Y- ROI-10.80% 52W High-50.14% Beta-
Dividend %- Quick Ratio6.40 Sales past 5Y- Gross Margin- 52W Low99.17% ATR0.84
Employees147 Current Ratio6.40 Sales Q/Q1626.10% Oper. Margin-11.30% RSI (14)66.44 Volatility5.36% 6.47%
OptionableYes Debt/Eq0.00 EPS Q/Q8.50% Profit Margin-17.70% Rel Volume1.04 Prev Close13.88
ShortableYes LT Debt/Eq0.00 EarningsNov 14 BMO Payout- Avg Volume116.30K Price14.46
Recom1.50 SMA2013.22% SMA509.34% SMA2003.18% Volume121,103 Change4.18%
May-11-18Upgrade Barclays Underweight → Equal Weight $8 → $15
Mar-19-18Initiated Raymond James Outperform
Dec-08-18 08:00AM  Zymeworks Submits Investigational New Drug (IND) Application for ZW49 and Presents IND-Enabling Studies at the San Antonio Breast Cancer Symposium Business Wire
Nov-27-18 06:58AM  BRIEF-Zymeworks, Beigene Announce License And Collaboration Agreement For Zymeworks' Her2-Targeted Therapeutic Candidates Reuters
06:30AM  Zymeworks and BeiGene Announce License and Collaboration Agreement for Zymeworks HER2-Targeted Therapeutic Candidates, ZW25 and ZW49, in Asia-Pacific and Research and License Agreement for Zymeworks Azymetric and EFECT Platforms Globally Business Wire
Nov-14-18 06:30AM  Zymeworks Announces Updated Clinical Data for Novel Bispecific Antibody, ZW25, Presented at the EORTC-NCI-AACR Symposium Business Wire
Nov-13-18 07:50AM  Recent Analysis Shows Cleveland-Cliffs, Optical Cable, Camtek, QIAGEN N.V, Value Line, and Zymeworks Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Nov-07-18 04:30PM  Zymeworks to Present at Upcoming Investor Conferences Business Wire
Nov-06-18 08:10PM  Zymeworks Inc. (ZYME) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:30PM  Zymeworks Reports Financial Results for the Third Quarter of 2018 Business Wire
Oct-30-18 06:45AM  Zymeworks Announces Selection of ZW25 Abstract for Plenary Session Presentation at the 30th EORTC-NCI-AACR Symposium Business Wire
Oct-23-18 06:45AM  Zymeworks and LEO Pharma Enter into Bispecific Antibody Licensing and Research Collaboration Business Wire
Oct-04-18 06:45AM  Zymeworks to Webcast R&D Briefing Business Wire
Sep-25-18 04:30PM  Zymeworks to Present at Ladenburg Thalmann 2018 Healthcare Conference Business Wire
Sep-19-18 06:45AM  Zymeworks Names Anthony Polverino, Ph.D., Executive Vice President of Early Development and Chief Scientific Officer Business Wire +5.87%
Sep-14-18 05:09PM  Eli Lilly Is Selling More Shares of This Biopharma Firm Barrons.com
Sep-05-18 01:49PM  Eli Lilly Has Trimmed Its Stake in Biopharma Firm Zymeworks Barrons.com
Sep-04-18 05:00PM  Zymeworks Reports IND-Submission Milestone Achieved in Lilly Collaboration Business Wire
Aug-29-18 04:30PM  Zymeworks to Present at Wells Fargo Healthcare Conference Business Wire
Aug-02-18 08:00AM  Zymeworks to Present at Canaccord Genuity 38th Annual Growth Conference Business Wire +7.98%
Aug-01-18 08:00AM  Zymeworks Reports Financial Results for the Second Quarter of 2018 Business Wire
Jun-11-18 09:36AM  Zymeworks Closes Previously Announced Public Offering Business Wire
Jun-07-18 07:50PM  Zymeworks Announces Election of Directors and Voting Results from Shareholder Meeting Business Wire
Jun-06-18 10:49PM  Zymeworks Announces Pricing of Public Offering Business Wire -11.02%
04:10PM  Zymeworks Files Preliminary Prospectus Supplement for Offering of Common Shares Business Wire
Jun-01-18 03:45PM  Clinical Data for Zymeworks Novel Bispecific Antibody, ZW25, Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting Business Wire +6.12%
May-14-18 05:00PM  Zymeworks and Daiichi Sankyo Expand Immuno-Oncology Collaboration Focused on Bispecific Antibodies Business Wire
May-10-18 04:30PM  Zymeworks to Present at the UBS Global Healthcare Conference 2018 Business Wire
May-01-18 04:05PM  Zymeworks Reports 2018 First Quarter Financial Results Business Wire
Apr-30-18 04:05PM  Zymeworks to Present at Bloom Burton & Co. Healthcare Investor Conference 2018 Business Wire
Apr-25-18 06:00AM  Zymeworks Announces Selection of ZW25 Abstract for Oral Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting Business Wire +6.31%
Apr-23-18 04:05PM  Zymeworks and Celgene Expand Bispecific Antibody Collaboration Business Wire
Apr-17-18 05:00AM  Zymeworks Presents Preclinical Data at the Annual Meeting of the American Association for Cancer Research Business Wire
Apr-03-18 11:39AM  Was Zymeworks Incs (TSE:ZYME) Earnings Growth Better Than The Industrys? Simply Wall St. -7.79%
Mar-14-18 04:05PM  Zymeworks Reports 2017 Year-End Financial Results Business Wire
04:05PM  Zymeworks Advances Clinical Candidate Incorporating Technology from Kairos Acquisition Business Wire
Mar-07-18 04:05PM  Zymeworks to Present at Barclays 2018 Global Healthcare Conference Business Wire
Feb-28-18 04:05PM  Zymeworks Opening Clinical Sites in Canada Business Wire
Jan-07-18 07:00PM  Zymeworks Highlights Key 2017 Accomplishments and Announces 2018 Priorities Business Wire
Dec-28-17 03:29PM  Lifshitz & Miller LLP Announces Investigation of Alon USA Partners, LP, Amplify Snack Brands, Inc., Kindred Healthcare, Inc., Pinnacle Entertainment, Inc., Regal Entertainment Group, Sigma Designs, Inc. and Zymeworks Inc. PR Newswire
Dec-20-17 10:03PM  ZYME INVESTOR ALERT: Law Offices of Howard G. Smith Commences Investigation on Behalf of Zymeworks Inc. Investors Business Wire
Dec-15-17 06:46AM  Zymeworks (ZYME) Alert: Johnson Fistel Announces Investigation of Zymeworks Inc.; Encourages Investors to Contact the Firm for Additional Information PR Newswire -6.27%
Dec-05-17 05:00AM  Zymeworks Presents Results of the Completed Dose Escalation Portion of the Ongoing Phase 1 Study of ZW25 at the San Antonio Breast Cancer Symposium Business Wire +6.86%
Nov-15-17 07:30AM  Featured Company News - Zymeworks Enters Into License Agreement with Janssen Biotech to Develop and Commercialize Next Generation Bispecific Antibody Therapeutics ACCESSWIRE
Nov-13-17 04:15PM  Zymeworks to Present at Upcoming 2017 Stifel Healthcare Conference Business Wire +24.75%
05:00AM  Zymeworks Announces License Agreement with Johnson & Johnson Innovation to Develop and Commercialize Next Generation Bispecific Antibody Therapeutics Business Wire
Nov-08-17 04:15PM  Zymeworks Reports Third Quarter 2017 Financial Results and Provides Business Update Business Wire
Sep-19-17 05:00AM  Merck to Advance Bispecific Antibody Drug Candidate Developed Using Zymeworks Azymetric Platform into Preclinical Development Business Wire
Sep-11-17 07:15AM  Zymeworks Presents Additional Safety and Anti-Tumor Activity Data from the Ongoing Phase 1 Study of ZW25 at the European Society for Medical Oncology 2017 Congress (ESMO) Business Wire
Sep-07-17 01:59PM  2 Names Barclays Is Now Bearish On In Biotech Benzinga -6.89%
Sep-06-17 05:00AM  Zymeworks to Present at the European Society for Medical Oncology 2017 Congress and Hold Webcast to Review Clinical Results Business Wire
Aug-29-17 05:00AM  Zymeworks to Participate in Upcoming Healthcare and Biotech Conferences Business Wire +7.71%
Aug-08-17 04:01PM  Zymeworks Reports Second Quarter 2017 Financial Results Business Wire
Aug-04-17 04:05PM  Zymeworks to Present at 37th Annual Canaccord Genuity Growth Conference Business Wire
Aug-03-17 05:00AM  Zymeworks Appoints Dr. Natalie Sacks to its Board of Directors Business Wire
Aug-01-17 04:30PM  Zymeworks to Host Second Quarter 2017 Financial Results Conference Call on August 8, 2017 Business Wire
Jul-18-17 05:00AM  Zymeworks and Daiichi Sankyo Announce Successful Achievement of a Research Milestone in Bispecific Antibody Collaboration Business Wire
Jun-12-17 07:00AM  Drug Candidates Developed Using Zymeworks Azymetric Platform Nominated for Late-Stage, Preclinical Development by Lilly Business Wire
Jun-04-17 09:00AM  Zymeworks Presents Safety and Anti-Tumor Activity Data from the Ongoing Phase 1 Study of ZW25 at the American Society of Clinical Oncology Annual Meeting (ASCO 2017) Business Wire
May-26-17 07:59AM  Zymeworks Announces Partial Exercise of Over-Allotment Option for its Initial Public Offering Business Wire
May-23-17 02:09PM  Zymeworks: Early But Compelling Data, Large Biopharma Partners And A Potential June Catalyst Benzinga
May-17-17 05:00PM  Zymeworks to Present at the 2017 American Society of Clinical Oncology Annual Meeting Business Wire
May-15-17 04:01PM  Zymeworks Reports First Quarter 2017 Financial Results Business Wire
Zymeworks Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The company's lead product candidate is ZW25, a novel bispecific antibody that is in Phase I clinical trial for the treatment of breast and gastric cancer. It is also developing ZW49, a bispecific antibody-drug conjugate that is in IND application stage. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Celgene Corporation and Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; and Janssen Biotech, Inc., as well as a collaboration agreement with Celgene Corporation. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies targeting cytokine-receptor pathways. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.